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Abstract 
Objective:  
To investigate and compare two ALS staging systems, King’s clinical staging and 
Milano-Torino (MiToS) functional staging, using data from the LiCALS Phase 3 
clinical trial (EudraCT 2008-006891-31).  
Methods:  
Disease stage was derived retrospectively for each system from the ALS Functional 
Rating Scale (Revised) subscores using standard methods. The two staging 
methods were then compared for timing of stages using box plots, correspondence 
between stages using chi square tests, and concordance using Spearman’s rank 
correlation.   
Results:  
For both systems, progressively higher stages occurred at progressively later 
proportions of the disease course, but the distribution differed between the two 
methods. King’s stage 3 corresponded to MiToS stage 1 most frequently, with earlier 
King’s stages largely corresponding to MiToS stage 0 or 1. The Spearman 
correlation was 0.54. 
Conclusion:  
The distribution of timings shows that the two systems are complementary, with 
King’s staging showing greatest resolution in early to mid-disease corresponding to 
clinical or disease burden, and MiToS staging having higher resolution for late 
disease, corresponding to functional involvement. We therefore propose using both 
when describing ALS disease stage. 
 
 
 
 
 
 
 
  
Introduction  
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is 
a progressive neurodegenerative disease of motor neurons in the brain and spinal 
cord, resulting in progressive paralysis, with death typically within 2 to 5 years of 
diagnosis (1). Although the cumulative lifetime risk of ALS is 1 in 300 (2), the point 
prevalence is only about 5 per 100,000 persons because of the poor prognosis. The 
needs of patients differ as ALS progresses, with diagnosis and therapist support 
being important early on, and respiratory intervention, nutritional intervention and 
end of life care at a later stage.  
 
Various ALS staging methods have been proposed, with uses such as a tool for 
rehabilitation (3), rapid functional assessment (4), comparison of different treatment 
models (5, 6), biomarker analysis (7) and health economics (8). The El Escorial 
criteria (9) provide a set of diagnostic guidelines that are based on patterns of 
disease spread but are not in themselves a staging system. The most widely studied 
approaches have been between the Milano-Torino (MiToS) functional staging and 
King’s clinical staging systems (10, 11). The MiToS system uses 6 stages, from 0 to 
5 and is based on functional ability as assessed by the ALS Functional Rating Scale 
Revised (ALSFRS-R) (12), with stage 0 being normal function and stage 5 being 
death. The King’s system uses 5 stages, from 1 to 5 and is based on disease burden 
as measured by clinical involvement and significant feeding or respiratory failure, 
with stage 1 being symptom onset and stage 5 being death. The King’s system is not 
based on ALSFRS-R scores, but can be estimated from them with 92% concordance 
(13). 
 
Although the two systems both measure stage and show content validity, mapping 
correctly to disease progression, it is not clear to what extent they are collinear and 
therefore redundant. We therefore set out to compare the systems using data from a 
phase 3 randomised double-blind placebo-controlled trial of lithium carbonate in ALS 
(LiCALS) (EudraCT number 2008-006891-31) (14), in which ALSFRS-R scores were 
recorded at 3 monthly intervals. 
 
  
Methods 
 
Patients  
Anonymised data from the LiCALS clinical trial was reanalysed. Data consisted of 
ALSFRS-R scores, site of disease onset (bulbar or limb), gastrostomy timing, 
measures of respiratory function, and timing of non-invasive ventilation, recorded 
every three months during an eighteen-month trial enrolment. For all patients, date of 
death or last follow-up were also recorded. 
   
Clinical staging systems 
ALS clinical stage comparisons were undertaken using two staging systems; King’s 
clinical staging and MiToS functional staging. As stages were not previously 
recorded during the LiCALS clinical trial, stages for both systems were determined 
retrospectively and derived from historical data, as previously described (11) (10) 
(Figure 1). For simplicity, we encoded King’s stages with prefix K, and MiToS stages 
with prefix M, so for example, K2M3 would represent King’s stage 2 and MiToS 
stage 3.  
 
Statistical analysis 
A Kaplan-Meier survival analysis and log-rank test were used to test differences in 
survival from disease onset for each categorical variable, site of onset (bulbar or 
spinal), family history (sporadic ALS or familial ALS), gender, and age of onset in 10-
year categories. We also tested the proportion of patients dead or alive using a chi 
square test after censoring the date of death or last observation of all patients to 
June the 30th, 2011.   
 
Standardised median times for reaching clinical stages were calculated as a 
proportion of time elapsed from onset to each disease stage across the duration of 
the disease for both King’s and MiToS systems, with 0 representing symptom onset, 
and 1, death, using only data from deceased patients, as previously described (11).  
 
Spearman’s coefficient was used to test overall correlation between the two systems. 
Pairwise comparisons between the number of patients in each King’s and MiToS 
stage were used to test the relationship between specific stages using a chi-square 
test. Standardised residuals were used to test which items were most responsible for 
any associations observed. Agreement between the two ordinal scales was tested 
using a linearly weighted kappa coefficient.  
 
Kappa coefficient was calculated using VassarStats 
(http://vassarstats.net/kappa.html). All other statistical tests were carried out using 
SPSS v22.0 (SPSS Inc, Illinois, USA). 
 
Ethics 
The LiCALS clinical study was ethically approved by the South East London 
Research Ethics Committee reference 09/H1102/15. All participants involved, 
provided written consent. This current study does not require ethical approval due to 
analysis being conducted on fully anonymised pre-existing clinical trial data. 
  
Results 
 
Patient characteristics 
Data was available for 217 patients, of whom 95 had died by the censor date. Patient 
characteristics are shown in Table 1. Median survival was 43.6 months, which is 
similar to that found in a previous study using referral clinic data, 42.3 months (11). 
There were no significant differences in survival by gender, family history or site of 
onset, and no differences were seen in the proportion still alive by the study end 
date. Older age at disease onset was associated with worse survival p=0.01, and 
consistent with this observation, the proportion of deaths compared with censored 
observations progressively increased as patients were classified into higher age 
groups: 56% of patients in the 75-84 year age group had died by the end of the trial, 
compared with only 14% for the 25-34 year age group.  
 
Standardised median time  
95 patients had died by the end of the study. The standardised median proportion of 
time elapsed from onset to each King’s stage is shown in Table 2a and Figure 2a. 
Corresponding values for MiToS stages are shown in Table 2b and Figure 2b, 
showing a wider distribution of King’s stages through the early and middle disease 
course, compared with a tendency for MiToS stages to be distributed later in the 
disease course. 
 
Comparison of staging systems  
To compare each staging system, King’s and MiToS scores were plotted against 
frequency for all pairwise comparisons (Figure 3). King’s stages 1 and 2 matched 
mostly with MiToS stages 0 or 1 (K1M0 n=151, K2M0 n=210, K1M1 n=35, K2M1 
n=100) with little overlap to MiToS stage 2 (K2M2 n=4) and none with MiToS stages 
3 and 4. However for King’s stage 3 although the majority was paired with MiToS 
stages 0 or 1 (K3M0 n=203, K3M1 n=211), more patients were defined as MiToS 
stages 2 (K3M2 n=37) and 3 (K3M3 n=11). In King’s stage 4 all four MiToS stages 
were seen (K4M0 n=8, K4M1 n=60, K4M2 n=77, K4M3 n=24, K4M4 n=6). A chi-
square test confirmed association between some stages with the two staging 
systems (p<0.001) and standardised residuals showed the strongest association was 
of King’s stage 4 with MiToS stage 2. A Spearman’s rank correlation coefficient 
between the King’s and MiToS systems showed a correlation of 0.54. A linearly 
weighted kappa coefficient between the two systems highlighted a kappa co-efficient 
of 0.21 with a 95% confidence interval of 0.18-0.24.  
 
 
  
Discussion  
We have found that while the King’s clinical staging system is able to differentiate 
early to mid-disease well, the MiToS staging is able to differentiate late stages in 
detail, which is in line with previous findings (15). These results support the use of 
both systems when staging, as they summarise two different aspects of patient 
information. King’s staging is mostly focussed on anatomical disease spread and 
significant involvement of respiratory muscles, whereas MiToS staging is aimed 
more towards the distinction of functional capabilities during the spread of the 
disease. Because functional engagement necessarily follows anatomical 
involvement, MiToS stages inevitably tend to lag behind King’s stages, manifesting 
as a higher resolution later on in the disease. This is most easily seen in Figure 3, 
where the relative distribution of individuals in each staging system is shown. The 
MiToS stages remains at a low resolution for the majority of King’s stages up until 
K4, at which point there is significant differentiation of the MiToS stages. 
 
These differences in disease description by the two systems are also shown by a 
Spearman’s rank correlation of 0.54, showing some correspondence between the 
two systems. Association testing shows that King’s stage 4 and MiToS stage 2 are 
the most strongly associated between all staging pairs. Linearly weighted kappa co-
efficient tests the strength of agreement between two ordinal scales with penalty 
increasing based on level of disagreement. A linear weighted kappa is a statistical 
analysis used to test agreement between two ordinal scales. A commonly used scale 
to interpret kappa ranges from 0 (chance agreement) to 1 (perfect agreement) with 
intervals of poor, slight, fair, moderate, substantial and almost perfect (REF – Landis 
and Koch, 1977). Our analysis between King’s and MiToS staging systems showed 
a fair agreement with a linearly weighted kappa coefficient of 0.21. 
 
Examination of the proportion of disease elapsed at each stage confirms that King’s 
stages show more resolution through early to mid-disease and MiToS stages 
towards the end. Patients in King’s stages 1, 2 and 3 are often in MiToS stages 0 or 
1. We found that King’s Stage 4 corresponds to MiToS stages 2, 3 and 4, and about 
80% to 90% of the disease course. The benefit of MiToS staging in differentiating 
later stages of disease is in contrast to the ALSFRS-R scores from which it was 
derived, that exhibits a floor effect and lack of sensitivity in the later stages 
(10,11,12). In other words, by combining information from different parts of the 
ALSFRS-R, MiToS staging is able to provide value over and above the ALSFRS-R 
score as a functional indicator for disease progression. 
 
A limitation of this study is its use of clinical trial data rather than clinic or population 
data. However, this may be advantageous, as results are more likely to be relevant 
to daily clinical practice. We have previously shown that clinical trial data show a shift 
towards a greater proportion of disease course passed for a given stage (13). This 
occurrence is likely a result of left censoring due to the population being selected for 
trial participation and sourced from a biased clinic population.  
 
The two disease staging systems described are complementary rather than 
redundant, and provide different types of information. King’s staging summarises the 
clinical or anatomical spread of disease, while MiToS staging summarises the 
functional burden of disease. A similar situation exists for cancers. The American 
Joint Committee on Cancer’s TNM scale allocates a score for size, lymph node 
infiltration and metastasis as a functional indicator for disease progression (16), and 
this is combined with grouping of patients into one of four clinical stages that 
determine overall disease progression. King’s stage prefixed K, and MiToS stage 
prefixed M, would allow a concise summary of disease spread and functional 
burden. We therefore propose using both to describe ALS stage. 
  
Acknowledgements 
This is work from two EU Joint Programme - Neurodegenerative Disease Research 
(JPND) projects (STRENGTH, ALS-CarE). The projects are supported through the 
following funding organisations under the aegis of JPND - www.jpnd.eu (United 
Kingdom, Medical Research Council and Economic and Social Research Council). 
AAC receives salary support from the National Institute for Health Research (NIHR) 
Dementia Biomedical Research Unit at South London and Maudsley NHS 
Foundation Trust and King’s College London. The work leading up to this publication 
was funded by the European Community’s Health Seventh Framework Programme 
(FP7/2007–2013; grant agreement number 259867). 
 
 
 
Conflicts of Interest 
None to declare.  
 
 
  
References: 
1. Knibb JA, Keren N, Kulka A, Leigh PN, Martin S, Shaw CE, et al. A clinical tool for 
predicting survival in ALS. J Neurol Neurosurg Psychiatry. 2016. 
2. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D, et al. Amyotrophic 
lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 
2006;253(12):1642-3. 
3. Sinaki M, Mulder DW. Rehabilitation techniques for patients with amyotrophic 
lateral sclerosis. Mayo Clin Proc. 1978;53(3):173-8. 
4. Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N. Amyotrophic 
lateral sclerosis severity scale. Neuroepidemiology. 1989;8(3):142-50. 
5. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in 
patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 
1998;55(4):526-8. 
6. Lacomblez L, Bensimon G, Douillet P, Doppler V, Salachas F, Meininger V. Xaliproden 
in amyotrophic lateral sclerosis: early clinical trials. Amyotroph Lateral Scler Other Motor 
Neuron Disord. 2004;5(2):99-106. 
7. Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, et al. Immune 
reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J 
Neurol Neurosurg Psychiatry. 2014;85(3):274-8. 
8. Oh J, An JW, Oh SI, Oh KW, Kim JA, Lee JS, et al. Socioeconomic costs of amyotrophic 
lateral sclerosis according to staging system. Amyotroph Lateral Scler Frontotemporal 
Degener. 2015;16(3-4):202-8. 
9. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research 
Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of 
amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 
2000;1(5):293-9. 
10. Chio A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of 
a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 
2015;86(1):38-44. 
11. Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed 
staging system for amyotrophic lateral sclerosis. Brain. 2012;135(Pt 3):847-52. 
12. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-
R: a revised ALS functional rating scale that incorporates assessments of respiratory 
function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1-2):13-21. 
13. Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw PJ, et al. Use of clinical 
staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg 
Psychiatry. 2015;86(1):45-9. 
14. Group UK-LS, Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, et al. 
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, 
randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(4):339-45. 
15. Ferraro D, Consonni D, Fini N, Fasano A, Del Giovane C, Emilia Romagna Registry for 
ALSG, et al. Amyotrophic lateral sclerosis: a comparison of two staging systems in a 
population-based study. Eur J Neurol. 2016;23(9):1426-32. 
16. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of 
the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4. 
 
